CLINICAL_TRIALS ClinicalTrials.gov record update

A New Option for Post-CDK4/6is Resistance Era: Multicenter Real-world Study of Anlotinib-based Combination Therapy in Hormone Receptor-positive Metastatic Breast Cancer Resistant to CDK4/6is.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06734533
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:03.033909+00:00
Published At: 2024-12-16T00:00:00+00:00
Record Updated At: 2024-12-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["HR+ Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-12-16"
protocolSection.identificationModule.nctId: "NCT06734533"
protocolSection.identificationModule.officialTitle: "A New Option for Post-CDK4/6is Resistance Era: Multicenter Real-world Study of Anlotinib-based Combination Therapy in Hormone Receptor-positive Metastatic Breast Cancer Resistant to CDK4/6is."
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.